Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H30N2O.ClH |
Molecular Weight | 374.947 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(C2=CC=CC=C2)C3=CC=CC=N3
InChI
InChIKey=HFIHPVIVQSWZBV-UBKAUKJESA-N
InChI=1S/C22H30N2O.ClH/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21;/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3;1H/t18-,19+,22-;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C22H30N2O |
Molecular Weight | 338.4864 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Curator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Pirmenol is an antiarrhythmic agent, which exhibits effects on the fast action potential similar to other class 1 membrane active antiarrhythmic agents. Pirmenol depresses not only the fast Na+ channel, but also others, such as the slow Ca2+ and K+ channels. Pirmenol had sevenfold lower affinity for glandular-type muscarinic receptors (M3) than for cardiac-type muscarinic receptors (M2). This medicine regulates disturbed pulse by acting on the cardiac muscle. Usually, used for treatment of tachyarrhythmia (ventricular). The most commonly reported adverse reactions include constipation, discomfort in stomach, difficulty in urination (urinary retention), headache, insomnia, bitterness in the mouth, nausea, dry mouth and palpitation. Lidocaine, procainamide and quinidine a greater degree of arrhythmia conversion occurred when dosed 15 min after pirmenol than when these agents were dosed alone.
CNS Activity
Originator
Sources: https://www.google.com/patents/US4112103
Curator's Comment: http://www.chemdrug.com/article/8/3284/16419223.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Fast sodium-channels (rabbit) |
|||
Target ID: Slow potassium channels (rabbit) |
|||
Target ID: Slow calcium channels (rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3241147 |
|||
Target ID: 1.00715344E8 Gene Symbol: Chrm2 |
|||
Target ID: 1.00379232E8 Gene Symbol: Chrm3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1381764 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PIMENOL Approved UseDrug is used for the treatment of tachyarrhythmia (ventricular). |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9600665
The IC50 of pirmenol for acetylcholine- and adenosine-induced current was about 1 and 8 microM in a single atrial myocytes
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:37 GMT 2023
by
admin
on
Fri Dec 15 15:25:37 GMT 2023
|
Record UNII |
JA79OMG4QT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
61477-94-9
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
DTXSID6021169
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
C024318
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
m8884
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL432103
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
76962233
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
C81547
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
SUB03874MIG
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
JA79OMG4QT
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY | |||
|
100000085333
Created by
admin on Fri Dec 15 15:25:37 GMT 2023 , Edited by admin on Fri Dec 15 15:25:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |